Prostate cancer remains the most common non-skin cancer diagnosed among men in the US, affecting more than 200,000 men annually. Treatment for localized prostate cancer, ranging from surgical removal of the prostate to radiation therapy, can result in substantial changes in urinary, sexual, and bowel function. Because prostate cancer is typically slow-progressing and has low mortality, these quality of life changes can be particularly impactful for prostate cancer survivors, and especially important for patients to consider when making treatment decisions.
CERTAIN is working with physicians and patients to develop quality improvement and research activities that will improve prostate cancer care in Washington State. Through Urology SCOAP (UroSCOAP), clinicians are gathering in‐hospital data about the use and outcomes of different prostate cancer interventions and receiving valuable benchmarking information that they can use to improve care. Physicians who treat prostate cancer are also involved in the Collaborative to Improve Native Cancer Outcomes (CINCO), a multi-faceted program to improve cancer health outcomes and quality of life among the American Indian/Alaska Native population. In addition, researchers and patients are working together to develop tools that integrate patient-reported quality of life and clinical metrics into decision tools that allow patients to evaluate their own preferences and learn the outcomes of “similar” patients, who are matched based on demographic and clinical characteristics and preference ratings for health states that are attributable to the treatment options under consideration.
CERTAIN is helping improve the quality of urology care by:
Contact us to indicate your interest in learning more about CERTAIN Urology Care activities.